The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
2
|
H02 | Corticosteroids for systemic use | |
3
|
H02A | CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN | |
4
|
H02AB | Glucocorticoids | |
5
|
H02AB02 | Dexamethasone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 1.5 mg | |
| PAREN | Parenteral | 1.5 mg |
| Active Ingredient |
|---|
|
Dexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. It has an approximately 7 times greater anti-inflammatory potency than prednisolone, another commonly prescribed corticosteroid. At high doses it reduces the immune response. |
| Document | Type | Information Source | |
|---|---|---|---|
| DECADRON Oral solution | MPI, US: SPL/Old | FDA, National Drug Code (US) | |
| DEXAMED Tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| DEXSOL Oral solution | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| NEOFORDEX Tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.